Amended Current Report Filing (8-k/a)
July 10 2019 - 01:47PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
July 1, 2019
Heyu
Biological Technology Corporation
(Exact
Name of Registrant as Specified in its Charter)
Nevada
|
|
000-26731
|
|
87-0627910
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification Number)
|
4th
Floor, No. 10 Building, Xinglin Bay Business Operation Center,
Jimei
District, Xiamen City,
Fujian
Province, China 361022
(Address
of Principal Executive Offices, Zip Code)
Registrant’s
telephone number, including area code:
(86) 158 5924 0902
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
None
|
|
None
|
|
None
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
EXPLANATORY
NOTE
On
July 1, 2019, Heyu Biological Technology Corporation, a Nevada corporation (the “Company”) filed a Current Report
on
Form 8-K
(the “Original Form 8-K”) with the Securities and Exchange Commission to report, among other things, the
Company agreed to pay its new directors, Mr. Stephen Truly Busch and Mr. Senad Busatlic, each $3,750 in cash per year for serving
on its board of directors, payable quarterly. This Amendment No. 1 on Form 8-K/A is being filed by the Company to amend Item 5.02
and Item 9.01 of the Original Form 8-K and correct the fact that the Company agreed to pay Mr. Busch and Mr. Busatlic each $15,000
in cash per year for serving on its board of directors, payable quarterly. Except as set forth in the foregoing, the Original
Form 8-K is unchanged.
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
|
Appointment
of New Directors
On
June 28, 2019, the board of directors (the “Board”) of Heyu Biological Technology Corporation, a Nevada corporation
(the “Company”), appointed Mr. Stephan Truly Busch as a director of the Company and Mr. Senad Busatlic as an independent
director of the Company, effective on July 1, 2019.
Mr.
Busch, 70, has served as a non-executive director of Heyu Leisure Holidays Corporation since March 2014, a Professor of Education
and Linguistics of Manipur International University since May 2019, an accreditation officer of International Accreditation Organization
since January 2014, an evaluation expert of California University Foreign Credentials Evaluation since 2010, a visiting professor
of Universidad Empresarial de Costa Rica since December 2010, and an external professor at Ansted University since September 2011.
Mr. Busch has been in the teaching profession for over 40 years at different schools in Germany, and is fluent in English, German,
Bosnian, Croatian, and Serbian. From June 1973 to July 2014, Mr. Busch worked as a high school teacher at Lessing-Realschule,
a school in Germany. Mr. Busch received his Ph.D. in Education in 2014 and his master’s degree in 2010 from Eastern Institute
for Integrated Learning in Management University.
On
April 16, 2019, the Company entered into a Director Offer Letter for a Director with Mr. Busch, attached hereto as
Exhibit
10.1
, pursuant to which the Company agreed to pay him $15,000 in cash per year for serving on the Board, payable quarterly,
and reimburse him for reasonable and approved expenses incurred by him in connection with the performance of his duties as a director.
There is no understanding or arrangement between Mr. Busch and any other person pursuant to which he was appointed as a director.
Neither Mr. Busch nor any of his immediate family members is a party to any transaction required to be disclosed pursuant to Item
404(a) of Regulation S-K.
Mr.
Busatlic, 43, has been an associate professor doctor in the field of Management Science since October 2015 and served as an assistant
professor doctor in the field of Management Science from October 2010 to October 2015 at International University of Sarajevo.
Mr. Busatlic has served as an expert in Project and Business Management in Organization for development and affirmation of society:
“Building New Lives” (BNL) in cooperation with Municipality Center since September 2012. Mr. Busatlic has had several
other positions at International University of Sarajevo. From April 2012 to June 2017, Mr. Busatlic served as the head of Department
of Economic and Management; from December 2014 to June 2016, Mr. Busatlic served as the coordinator of Leadership and Entrepreneurship
Center; from January 2011 to April 2012, Mr. Busatlic served as the vice rector for Research and External Affairs; from October
2010 to January 2011, Mr. Busatlic served as the vice dean for Faculty of Business Administration. From June 2009 to October 2010,
Mr. Busatlic served as a business development advisor for Akova Impex d.o.o. From June 2007 to March 2009, Mr. Busatlic served
as an executive director of Europapier-Hercegtisak d.o.o. Mr. Busatlic has published a book and many scientific papers in the
fields of economics and management. Mr. Busatlic received his Ph.D. in Economics from Braca Karic University Beograd in 2010 and
his master’s degree in Economics from International University at Novi Pazar in 2008.
On
April 16, 2019, the Company entered into a Director Offer Letter for an Independent Director with Mr. Busatlic, attached hereto
as
Exhibit 10.2
, pursuant to which the Company agreed to pay him $15,000 in cash per year for serving on the Board,
payable quarterly, and reimburse him for reasonable and approved expenses incurred by him in connection with the performance of
his duties as a director. There is no understanding or arrangement between Mr. Busatlic and any other person pursuant to which
he was appointed as a director. Neither Mr. Busatlic nor any of his immediate family members is a party to any transaction required
to be disclosed pursuant to Item 404(a) of Regulation S-K.
Item
9.01
|
Financial
Statements and Exhibits
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Heyu
Biological Technology Corporation
|
|
|
|
|
By:
|
/s/
Ban
Siong Ang
|
|
Name:
|
Ban
Siong Ang
|
|
Title:
|
Chief
Executive Officer
|
|
|
|
|
Dated:
|
July
10, 2019
|
3
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Mar 2023 to Mar 2024